» Articles » PMID: 3080696

MPTP: a Neurotoxin Relevant to the Pathophysiology of Parkinson's Disease. The 1985 George C. Cotzias Lecture

Overview
Journal Neurology
Specialty Neurology
Date 1986 Feb 1
PMID 3080696
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) elicits selective destruction of nigrostriatal dopamine neurons in humans and animals along with clinical symptoms of parkinsonism. Recent studies clarify mechanisms accounting for this neurotoxicity. MPTP binds with high affinity to monoamine oxidase, which transforms it to the pyridinium MPP+ . MPP+ is selectively concentrated by the dopamine neuronal uptake system. In nigral cells, binding by melanin of MPP+ affords a "depot" release mechanism to maintain prolonged high intracellular concentrations sufficient to destroy cells. PC-12 cells provide a model catecholamine cell culture for screening environmentally occurring substances that may be relevant in the etiology of idiopathic Parkinson's disease.

Citing Articles

Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1.

Liu Y, Lear T, Verma M, Wang K, Otero P, McKelvey A JCI Insight. 2020; 5(11).

PMID: 32493843 PMC: 7308049. DOI: 10.1172/jci.insight.131834.


Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease.

Franco R, Rivas-Santisteban R, Reyes-Resina I, Navarro G, Martinez-Pinilla E Front Aging Neurosci. 2020; 12:12.

PMID: 32226375 PMC: 7080700. DOI: 10.3389/fnagi.2020.00012.


Estimated Residential Exposure to Agricultural Chemicals and Premature Mortality by Parkinson's Disease in Washington State.

Caballero M, Amiri S, Denney J, Monsivais P, Hystad P, Amram O Int J Environ Res Public Health. 2018; 15(12).

PMID: 30558363 PMC: 6313412. DOI: 10.3390/ijerph15122885.


Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Masilamoni G, Groover O, Smith Y Neurobiol Dis. 2017; 100:9-18.

PMID: 28042095 PMC: 5511687. DOI: 10.1016/j.nbd.2016.12.025.


Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Mack J, Schamne M, Sampaio T, Pertile R, Fernandes P, Markus R Oxid Med Cell Longev. 2016; 2016:3472032.

PMID: 27829983 PMC: 5088323. DOI: 10.1155/2016/3472032.